Abstract
Background: Cell-free DNA (cfDNA) and circulating tumour cells (CTCs) can be measured in blood and provide a “liquid biopsy” as a surrogate for the tumour for real-time monitoring of patients with cancer. We aimed to find a clear relationship between this “liquid biopsy” biomarkers and other clinical characteristic, as blood biomarkers, receptor status, treatment or response to treatment, and test whether or not is possible to use them as prognostic indicators to predict overall survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
